Steering an enzyme's 'scissors' shows potential for stopping Alzheimer's disease

July 19, 2017, University of British Columbia
How one amino acid can spell the difference between a healthy aging brain and early onset Alzheimer's disease. Credit: Brian Kladko and Weihong Song/University of British Columbia

The old real estate adage about "location, location, location" might also apply to the biochemical genesis of Alzheimer's disease, according to new research from the University of British Columbia.

Scientists had previously identified a couple of crucial steps in the formation of a called amyloid beta, which accumulates in clumps, or "plaques," in the brains of people with Alzheimer's disease. Those discoveries inspired efforts at disrupting the biochemical carving of amyloid beta's into its final, toxic shape.

The latest drugs being tested try to silence an enzyme, called BACE1, that cuts the precursor protein. But BACE1 has other functions that are beneficial, so stopping it altogether could bring unwanted side effects—including disrupting the production of myelin, the protective insulation of brain cells.

Psychiatry Professor and Alzheimer's researcher Weihong Song has found that changing where the cut is made—in effect, guiding the enzyme's scissors to a different point—could achieve the same goal, with less collateral damage.

Song built upon two discoveries in the past decade of two rare : one found in Italian people that leads to early onset Alzheimer's disease, and another found in Icelandic people that staves off Alzheimer's disease.

Dr. Song's team at UBC's Townsend Family Laboratories was particularly intrigued by the diametrically opposite effects of both mutations because they affected the same point on the precursor protein's chain of 770 amino acids, swapping one acid for another.

As Dr. Song and his team describe in the July 19 issue of the Journal of Neuroscience, they injected one set of mice with a virus carrying the Italian gene mutation, and another set with the Icelandic mutation.

They found that the amino acid substitution affected where the precursor protein was cleaved. The Icelandic mutation resulted in a shortened form of amyloid beta, which does not become "sticky" and turn into plaque. The Italian mutation produced a longer, "stickier" version of , which ultimately becomes neuron-smothering plaque.

Actually, the effects were a matter of degree: Each mutation led to more cuts in one or more cuts in the other location. But in the gradual degradation of Alzheimer's , that could be enough - reducing the levels of the offending toxin could translate into many more years of life before cognitive decline sets in.

"If we can adjust where BACE1 cuts the protein, we will have a very precise way of slowing the build-up of plaque in the brain, without affecting other processes," says Dr. Song, a Canada Research Chair in Alzheimer's Disease and the Jack Brown and Family Professor. "This provides a new target in our search for a drug - instead of sledgehammer, it's more like a scalpel."

Explore further: Alzheimer's researcher reveals a protein's dual destructiveness—and therapeutic potential

More information: Shuting Zhang et al, BACE1 cleavage site selection critical for amyloidogenesis and Alzheimer's pathogenesis, The Journal of Neuroscience (2017). DOI: 10.1523/JNEUROSCI.0340-17.2017

Related Stories

Alzheimer's researcher reveals a protein's dual destructiveness—and therapeutic potential

December 3, 2012
A scientist at the University of British Columbia and Vancouver Coastal Health has identified the molecule that controls a scissor-like protein responsible for the production of plaques – the telltale sign of Alzheimer's ...

Gene mutation may speed up memory loss in Alzheimer's disease

May 3, 2017
A gene mutation may accelerate the loss of memory and thinking skills in people who are at risk for Alzheimer's disease, according to a study published in the May 3, 2017, online issue of Neurology, the medical journal of ...

Road block as a new strategy for the treatment of Alzheimer's

August 22, 2011
Blocking a transport pathway through the brain cells offers new prospects to prevent the development of Alzheimer's. Wim Annaert and colleagues of VIB and K.U. Leuven discovered that two main agents involved in the inception ...

Alzheimer's genetics point to new research direction

June 27, 2016
A University of Adelaide analysis of genetic mutations which cause early-onset Alzheimer's disease suggests a new focus for research into the causes of the disease.

How protein fragments associated with Alzheimer's could trigger Parkinson's

October 12, 2016
Alzheimer's and Parkinson's diseases are different neurodegenerative conditions that can sometimes affect the same person, which has led scientists to investigate possible links between the two. Now one team, reporting in ...

Recommended for you

Cell therapy could improve brain function for Alzheimer's disease

March 15, 2018
Like a great orchestra, your brain relies on the perfect coordination of many elements to function properly. And if one of those elements is out of sync, it affects the entire ensemble. In Alzheimer's disease, for instance, ...

Physically fit women nearly 90 percent less likely to develop dementia

March 14, 2018
Women with high physical fitness at middle age were nearly 90 percent less likely to develop dementia decades later, compared to women who were moderately fit, according to a study published the March 14, 2018, online issue ...

Poor sleep may heighten Alzheimer's risk

March 12, 2018
(HealthDay)—Older adults who are sleepy during the day might have harmful plaque building in their brain that is a sign of impending Alzheimer's disease, researchers report.

Dementia patients with distorted memories may actually retain key information – researchers say

March 7, 2018
Some memories containing inaccurate information can be beneficial to dementia sufferers because it enables them to retain key information researchers say.

The brain's immune system may be key to new Alzheimer's treatments

March 7, 2018
Sanford Burnham Prebys Medical Research Institute (SBP) researchers have published two new studies in Neuron that describe how TREM2, a receptor found on immune cells in the brain, interacts with toxic amyloid beta proteins ...

Study reveals novel biomarkers for future dementia risk

March 6, 2018
Sudha Seshadri, M.D., founding director of the Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases at UT Health San Antonio, is co-leader and senior author on research announced March 6 that identifies novel ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.